Brief points covered in the America Association for Cancer Research (AACR) Virtual Annual Meeting I held on April 27-28th:
-Treating BRAF-Positive Melanoma by adding checkpoint inhibitor Tecentriq (atezolizumab) to a combination of two targeted drugs Zelboraf (vemurafenib) and Cotellic (cobimetinib)
-PARP Inhibitor (targeted drugs that inhibit DNA damage repair) are approved by the FDA for the treatment of ovarian, breast, and pancreatic cancers.
-MET-inhibitor shows efficacy for non-small cell lung cancer and related brain metastases
-DETECT-A as the first to test a multicancer screening blood test in health patients and use results to guide further care
-COVID-19 and Cancer
For more information, see: https://www.cancertodaymag.org/Pages/cancer-talk/May-1-The-Week-in-Cancer-News.aspx
